Jens Forster, LL.M.
Attorney at law
email: jens.forster@forster-legal.de
phone: + 49 89 17 95 30 86
mobile: +49 1551 007 9508
fax: + 49 89 17 87 66 98
Education and career
2005 - 2011
Eberhard Karls University of Tübingen
Law studies and First State Examination
Focus on commercial and antitrust law
2011 - 2013
District Court of Passau
Legal clerkship and Second State Examination
2012 - 2013
Rinne Legal, Walnut Creek, CA, USA
Internship
Insolvency law
2013 - 2021
Weitnauer Attorneys-at-Law (Munich)
Attorney at law/Salary Partner
Life Sciences Team
2016 - 2017
Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim)
Secondment
2017 - 2019
Philipps University of Marburg
Master of Laws (LL.M.), pharmaceutical law
2021 - 2024
Alvotech Germany GmbH
In-house lawyer
Legal Head of Commercial
since 2024
Forster Legal
Attorney at law, founder
Law firm for pharmaceutical and medical device law
Achievements
- Advised major international companies and concerns in the pharmaceutical and medtech industry on international commercial agreements with customers, suppliers or academic partners.
- Worked both in law firms and pharmaceutical companies on the side of originators as well as biosimilars to provide guidance on business and legal aspects to its internal teams in international transactions.
- Implemented structures for legal processes and standardized contracts to be drafted, negotiated and managed in tough timelines for various clients.
- Enjoyed profound education both domestically and abroad and developped superior interpersonal communication and presentation skills, both in English and German language.
Publications (selection)
Dr. Timo Ehmann, Jens Forster LL.M.:
Implementation of the Consumer Rights Directive – Part 1: The new “general part” of consumer protection law
Dr. Tobias Krätzschmar, Jens Forster LL.M.:
The new EU regulation on clinical trials
Jens Forster, LL.M.:
The liability of the legal representative
Jens Forster, LL.M.:
The liability of the new co-sponsor
Ellen Bergmann, LL.M., Jens Forster, LL.M.:
The civil liability of the pharmaceutical company in individual therapeutic attempts
